Drug combo tested to fight aggressive blood vessel cancer
NCT ID NCT01303497
Summary
This study tested whether adding the drug bevacizumab to standard weekly paclitaxel chemotherapy helps control advanced angiosarcoma, a rare and aggressive cancer of blood vessels. It involved 70 adults whose cancer had spread or could not be removed by surgery. Patients were randomly assigned to receive paclitaxel alone or paclitaxel plus bevacizumab to compare how well the treatments stopped the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre René Gauducheau
Saint-Herblain, 44805, France
-
Centre Val d'Aurelle
Montpellier, 34298, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut Curie
Paris, 75005, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, 42270, France
Conditions
Explore the condition pages connected to this study.